BRIEF-Acumen Pharmaceuticals, Inc. Q3 Income From Operations USD -25.813 Million Vs. IBES Estimate USD -30.7 Million
Reuters2026/10/26 11:01Oct 26 (Reuters) - Acumen Pharmaceuticals, Inc. Q3 operating expenses USD 25.813 million.
- Q3 net income USD -25.369 million vs. IBES estimate USD -30.3 million
- Q3 basic EPS USD -0.35
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.
After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.
Hong Kong live music service provider Guitar Group applies for US IPO, aiming to raise $31 million
Guitar Group, a provider of music performance events, guitar-making workshops, and guitar repair services, submitted an application to the U.S. Securities and Exchange Commission (SEC) on Thursday, seeking to raise up to $31 million through an initial public offering (IPO).
Crypto prices
More
